Home > Resources > Whitepapers > THERAPEUTIC GENE EDITING:

THERAPEUTIC GENE EDITING:

November 21, 2016

Gene editing* is a process that repairs or changes a gene. Medical researchers are exploring ways to use gene editing to treat or prevent human diseases. According to a recent public opinion survey, Americans are both excited and concerned about this. 1 Given the complexity of gene editing and the rapid pace at which the science is progressing, it is no wonder that the public is both intrigued and perhaps uneasy

Spotlight

P3 Health Partners Nevada

P3 Health Partners (P3) is a patient-centered, physician-led and population health-focused healthcare company. Founded and led by physicians, Sherif Abdou, and Amir Bacchus, P3 is a team of doctors, clinicians and support service professionals with a shared passion and purpose for improving the way patient care is delivered.

OTHER WHITEPAPERS

Imaweld® heat sealable & weldable tube bioprocess media

whitePaper | February 3, 2023

Imaweld® is thermoplastic elastomer tubing particularly designed to transfer critical fluid in pharmaceutical and biopharmaceutical applications.

Scalable Rubella production in scale-X™ bioreactor with MRC-5 cells

whitePaper | November 18, 2022

Due to vaccine delivery gap for Rubella disease, global immunization is still limited in some parts of the world. In this paper we will demonstrate how one scale-X™ carbo fixed-bed bioreactor system.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

IoT To The Rescue For Biotech & Pharma Manufacturing

whitePaper | April 7, 2020

The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.

The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.